ASTX727
Near Add Your Location
Accepting patients
MyeloMATCH Master Protocol
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
- Genetic Sequencing
- Phase 2
Not yet accepting
ASTX727 in Patients with Hepatic Impairment
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Moderate and Severe Hepatic Impairment
- Chemotherapy
- Hypomethylating Agents (HMA)
- Phase 1
Accepting patients
Decitabine and Cedazuridine (ASTX727)
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Severe Renal Impairment and Cancer Patients With Normal Renal Function
- Cytidine Deaminase Inhibitor
- DNMT1 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 1